UCD19 CAR T cells

CD19-directed chimeric antigen receptor T cells (UCD19 construct) · University of Colorado, Denver

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UCD19 CAR T cells, covering 2025-05-15 to 2025-05-15. Get the full timeline:

Most recent: Clinical Trial Update: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1]

See pricing